Satisfaction among health plan members with their prescription drug coverage was studied. Interviews of patrons of 10 randomly selected community pharmacies in the Pittsburgh area were conducted by entry-level Pharm.D. students during spring 1999. Survey participants were asked to indicate their level of satisfaction with each of nine items dealing with various components of pharmacy benefit plans and to provide health-related and sociodemographic information. Differences in responses were assessed with univariate and multivariate statistics. A total of 504 people were interviewed. The results of general linear model and multivariate procedures indicated that the sociodemographic characteristics of respondents did little to explain variations in satisfaction. Differences were governed primarily by having a choice of plans in which to enroll and of perceptions of plan limitations. Most respondents were overwhelmingly satisfied with the quality of their prescription drug plans. Government-sponsored plans were rated at least as well as private plans. Members of health care plans in a metropolitan region were satisfied with their prescription drug coverage. Satisfaction was primarily determined by perceptions about coverage limitations and having a choice of plans.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ajhp/58.12.1110 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A pilot study on craving and its relationship to self-ratings of depression and anxiety in prescription opioid use disorder.
Exp Clin Psychopharmacol
January 2025
Substance Use and Concurrent Disorders Program, Royal Ottawa Mental Health Centre.
The role of craving in opioid use disorder (OUD) has been well established with respect to heroin but less so with prescription opioids. This pilot study, conducted in 18 treatment-seeking patients with prescription OUD and 18 healthy volunteers, assessed spontaneous (in the moment) and cue-induced craving and their relationship to depression and anxiety. Patients (vs.
View Article and Find Full Text PDFCKD-Associated Pruritus is Associated with Greater Use of Antidepressants and Anti-pruritus Medications.
Adv Ther
January 2025
CSL Vifor, Glattbrugg, Switzerland.
Introduction: Chronic kidney disease-associated pruritus (CKD-aP) is a common, yet underdiagnosed condition among patients on hemodialysis. Considering the lack of established treatment pathways, we sought to evaluate the use of antidepressant, systemic antihistamines, or gabapentinoid medications among patients with CKD-aP in the year following pruritus assessment.
Methods: We included 6209 patients on hemodialysis in the analysis.
The opioid crisis has been an issue in the United States since the mid-1990s, claiming numerous lives and presenting a significant challenge to health care clinicians. Various preoperative, intraoperative, and postoperative strategies aimed at reducing opioid consumption can be used by orthopaedic surgeons to help minimize this crisis. Preoperative screening tools can help identify patients at risk for prolonged opioid use, allowing for tailored interventions and counseling.
View Article and Find Full Text PDFUnregulated male sexual enhancement treatments: Perils and pitfalls for patients and providers.
J Am Assoc Nurse Pract
January 2025
Center for AIDS Preventions Studies (CAPS), University of California San Francisco, San Francisco, California.
As the demand for "quick-fixes" and instant gratification intensifies among consumers of the US health care delivery system, health care providers remain essential to ensuring patients receive safe, evidenced-based care. Erectile dysfunction is a common health condition affecting as many as 42% of US men. As such, it is unsurprising that American health care consumers affected by erectile dysfunction (ED) may be tempted by "quick fixes" to ameliorate their symptoms-particularly if such fixes are perceived to be less embarrassing, more accessible, and/or more affordable.
View Article and Find Full Text PDFPersistence of Lithium Underutilization in Patients of African Ancestry with Bipolar Disorder.
Psychopharmacol Bull
January 2025
Frye, MD, Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
Bipolar disorder is a chronic disease that imposes a lifelong burden on those that suffer from it. Lithium is still considered both gold standard treatment and first-line maintenance treatment, and access to treatment with lithium is paramount to improving patient outcomes. However, access to adequate treatment is not only contingent on symptom recognition, accurate diagnosis, and individualization of treatment, but also affected by racial and ethnic disparities at each stage of patient experience.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!